Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487338 | 0.90 | TMEM97 (0.47) | TMEM97SIGMAR1CYP1A2CYP3A4GRM5 | |
| SCHEMBL6486125 | 0.90 | CLPP (0.42) | PTGDR2TMEM97SIGMAR1 | |
| SCHEMBL6498920 | 0.90 | OPRM1 (0.44) | PTGDR2TMEM97SIGMAR1 | |
| SCHEMBL6501893 | 0.89 | TMEM97 (0.43) | PTGDR2TMEM97SIGMAR1 | |
| SCHEMBL6499661 | 0.88 | TMEM97 (0.43) | PTGDR2TMEM97SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL6484787 | 0.87 | TMEM97 (0.42) | PTGDR2TMEM97SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL6487329 | 0.87 | TMEM97 (0.43) | PTGDR2TMEM97SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL6489882 | 0.87 | TMEM97 (0.43) | PTGDR2TMEM97SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL6503118 | 0.85 | TMEM97 (0.43) | TMEM97SIGMAR1CYP1A2CYP3A4GRM5 | |
| SCHEMBL6485731 | 0.83 | PTGDR2 (0.42) | PTGDR2TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | PTGDR2 591/4885ENPP2 974/4885ATXN2 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.